Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Allison Berger"'
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Alexey V. Danilov, Jennifer R. Brown, J. Claire Godbersen, Cody Paiva, Olga V. Danilova, Allison Berger
Publikováno v:
Leukemia & Lymphoma. 56:1566-1569
Chronic lymphocytic leukemia (CLL) B-cells demonstrate both constitutive and stroma-mediated activation of nuclear factor-κB (NF-κB). NEDD8, a ubiquitin-like protein, regulates activity of Cullin-RING ubiquitin ligases (CRLs) and thus indirectly co
Autor:
Anindya Dutta, Amir A. Jazaeri, Etsuko Shibata, Jonghoon Park, Michael Milhollen, Susan C. Modesitt, Allison Berger, Mark R. Conaway, Jennifer Bryant, Peter G. Smith
Publikováno v:
Molecular Cancer Therapeutics. 12:1958-1967
The nearly ubiquitous development of chemoresistant disease remains a major obstacle against improving outcomes for patients with ovarian cancer. In this investigation, we evaluated the preclinical activity of MLN4924, an investigational inhibitor of
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Autor:
Isere Kuiatse, Hua Wang, Nibedita Chattopadhyay, Robert Z. Orlowski, Saurabh Menon, Judy Qiuju Shi, Junling Zhuang, Hans C. Lee, Vaishali Shinde, Allison Berger, Marc L. Hyer, Anna Kreshock, Stephen Tirrell, Sakeena Syed, Jie Yu, Richard J. Jones, Fazal Shirazi
Publikováno v:
Blood. 128:3296-3296
Background: The ubiquitin-proteasome system (UPS) has been validated as a target in multiple myeloma (MM) through the success of proteasome inhibitors such as bortezomib, but drug resistance is an emerging challenge. Targeting some of the upstream co
Autor:
Xiaozhen J. Liu, Eric S. Lightcap, Allison Berger, Khristofer Garcia, Jonathan L. Blank, Erik Koenig, David C. Bouck, Mike Kuranda, Hugues Bernard
Publikováno v:
Molecular Cancer Therapeutics. 14:C55-C55
Platinum-based therapies, both cisplatin and carboplatin, are utilized as part of first-line standard of care regimens for advanced non-small cell lung cancer (NSCLC), but overall response rate and overall survival remain limited, with a 5-year survi
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som
Autor:
Allison Berger, Steven P. Langston, Usha Narayanan, Ben Amidon, Sells Todd B, Jennifer Duffy, Teresa A. Soucy, Michael Milhollen, Peter G. Smith
Publikováno v:
Blood. 112:3621-3621
Successful therapeutic intervention in the ubiquitin-proteasome system (UPS) in multiple myeloma and mantle cell lymphoma with proteasome inhibitors has led to the pursuit of additional targets within the UPS. Through this effort we have identified M